BlueWave

Blue Wave Therapeutics is a Swiss-based biotechnology company specializing in the development of targeted radionuclide therapies for solid tumors. The company's core innovation is its proprietary radioactive biopolymer platform, which utilizes targeted alginate nanoparticles to deliver alpha-emitting radionuclides, such as Actinium-225, directly to cancer cells. Its lead candidate, ARAspheres, is designed to treat glioblastoma by targeting integrin receptors with high precision, thereby minimizing damage to surrounding healthy brain tissue. Beyond glioblastoma, Blue Wave is exploring the application of its platform in other aggressive cancers, including brain metastases and various solid tumors.